Karen S. Acker

Array ( [id] => 15708777 [patent_doc_number] => 20200101154 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-02 [patent_title] => TOLEROGENIC SYNTHETIC NANOCARRIERS FOR ANTIGEN-SPECIFIC DELETION OF T EFFECTOR CELLS [patent_app_type] => utility [patent_app_number] => 16/536154 [patent_app_country] => US [patent_app_date] => 2019-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34045 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16536154 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15083261 [patent_doc_number] => 20190336441 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-07 [patent_title] => METHOD FOR TREATING ATROPHIC AGE RELATED MACULAR DEGENERATION [patent_app_type] => utility [patent_app_number] => 16/516411 [patent_app_country] => US [patent_app_date] => 2019-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11494 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16516411 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15345355 [patent_doc_number] => 20200010569 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-09 [patent_title] => BISPECIFIC BINDING MOLECULES BINDING TO VEGF AND ANG2 [patent_app_type] => utility [patent_app_number] => 16/515231 [patent_app_country] => US [patent_app_date] => 2019-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32028 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -38 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16515231 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17060120 [patent_doc_number] => 11104707 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-31 [patent_title] => Multivalent CD20-binding molecules comprising Shiga toxin a subunit effector regions and enriched compositions thereof [patent_app_type] => utility [patent_app_number] => 16/515829 [patent_app_country] => US [patent_app_date] => 2019-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 15 [patent_no_of_words] => 76134 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 129 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16515829 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17435940 [patent_doc_number] => 11261252 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-03-01 [patent_title] => Molecules with specificity for CD79 and CD22 [patent_app_type] => utility [patent_app_number] => 16/513002 [patent_app_country] => US [patent_app_date] => 2019-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 34 [patent_no_of_words] => 44637 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 530 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16513002 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19777430 [patent_doc_number] => 12226451 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-18 [patent_title] => FGF-21 formulations [patent_app_type] => utility [patent_app_number] => 17/257530 [patent_app_country] => US [patent_app_date] => 2019-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 38128 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 141 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17257530 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17554965 [patent_doc_number] => 11311622 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-04-26 [patent_title] => Development of masked therapeutic antibodies to limit off-target effects [patent_app_type] => utility [patent_app_number] => 16/460957 [patent_app_country] => US [patent_app_date] => 2019-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 45 [patent_figures_cnt] => 67 [patent_no_of_words] => 12852 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16460957 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15800261 [patent_doc_number] => 20200123273 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-23 [patent_title] => THERAPEUTIC USE OF MITOCHONDRIA AND COMBINED MITOCHONDRIAL AGENTS [patent_app_type] => utility [patent_app_number] => 16/451910 [patent_app_country] => US [patent_app_date] => 2019-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26290 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16451910 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16949474 [patent_doc_number] => 20210208165 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-08 [patent_title] => PROTEIN BIOMARKERS FOR NEPHROPATHY AND APPLICATIONS THEREOF [patent_app_type] => utility [patent_app_number] => 17/253821 [patent_app_country] => US [patent_app_date] => 2019-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9169 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17253821 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19779552 [patent_doc_number] => 12228582 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-18 [patent_title] => Method and apparatus for testing near infrared-photoimmunotherapy treatment [patent_app_type] => utility [patent_app_number] => 17/253671 [patent_app_country] => US [patent_app_date] => 2019-06-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 3287 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 161 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17253671 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16876875 [patent_doc_number] => 11026995 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-06-08 [patent_title] => Use of CD24 for lowering low-density lipoprotein cholesterol levels [patent_app_type] => utility [patent_app_number] => 16/443498 [patent_app_country] => US [patent_app_date] => 2019-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 12 [patent_no_of_words] => 9195 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16443498 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16948111 [patent_doc_number] => 20210206802 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-08 [patent_title] => MONOTHIOETHER CROSSLINKERS IN POLYMERS AND APPLICATIONS THEREOF [patent_app_type] => utility [patent_app_number] => 17/250094 [patent_app_country] => US [patent_app_date] => 2019-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6939 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17250094 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17975523 [patent_doc_number] => 11492371 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-08 [patent_title] => Production of heterodimeric proteins [patent_app_type] => utility [patent_app_number] => 16/426647 [patent_app_country] => US [patent_app_date] => 2019-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 115 [patent_figures_cnt] => 191 [patent_no_of_words] => 70663 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 206 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16426647 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15209891 [patent_doc_number] => 20190367632 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-05 [patent_title] => THERAPEUTIC ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/427146 [patent_app_country] => US [patent_app_date] => 2019-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37238 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 182 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16427146 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17713513 [patent_doc_number] => 11377496 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-07-05 [patent_title] => Targeting agent antibody conjugates and uses thereof [patent_app_type] => utility [patent_app_number] => 16/420062 [patent_app_country] => US [patent_app_date] => 2019-05-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 48 [patent_no_of_words] => 40190 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 8 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16420062 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16861756 [patent_doc_number] => 11020478 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-06-01 [patent_title] => Methods for modulating angiogenesis of cancers refractory to anti-VEGF treatment [patent_app_type] => utility [patent_app_number] => 16/416996 [patent_app_country] => US [patent_app_date] => 2019-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 88 [patent_no_of_words] => 30852 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 199 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16416996 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16221207 [patent_doc_number] => 20200246323 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-06 [patent_title] => Antibody Drug Conjugates with Cell Permeable BCL-XL Inhibitors [patent_app_type] => utility [patent_app_number] => 16/412729 [patent_app_country] => US [patent_app_date] => 2019-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56387 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -90 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16412729 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17482252 [patent_doc_number] => 20220089756 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-24 [patent_title] => BISPECIFIC ANTIBODIES WITH CLEAVABLE C-TERMINAL CHARGE-PAIRED TAGS [patent_app_type] => utility [patent_app_number] => 17/053728 [patent_app_country] => US [patent_app_date] => 2019-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16310 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -47 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17053728 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15647219 [patent_doc_number] => 20200086139 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-19 [patent_title] => COMBINATION THERAPY FOR THE TREATMENT OF GLIOBLASTOMA [patent_app_type] => utility [patent_app_number] => 16/397104 [patent_app_country] => US [patent_app_date] => 2019-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13831 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16397104 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15345347 [patent_doc_number] => 20200010565 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-09 [patent_title] => TREATMENT OF OCULAR DISEASE [patent_app_type] => utility [patent_app_number] => 16/395972 [patent_app_country] => US [patent_app_date] => 2019-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14389 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16395972 [rel_patent_id] =>[rel_patent_doc_number] =>)